Prelude Therapeutics Cash Flow Statement (2024-2025) | PRLD

Cash Flow Statement Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Operating Activities
Net Income -34.38M-33.83M-20.42M
Share-based Compensation 5.55M6.10M5.93M3.77M3.83M3.81M2.42M
Gains from Sales and Divestitures 0.03M0.03M0.03M0.04M0.01M0.02M0.03M
Gains from Investment Securities -0.46M-0.06M0.76M0.15M16.64M0.05M
Non-cash Items 6.40M7.70M0.50M8.52M8.82M0.01M9.63M
Cash from Operations -31.79M-23.06M-27.30M-20.74M-34.23M-26.07M-19.11M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 1.54M1.33M0.81M0.95M0.38M0.38M0.38M
Depreciation & Amortization (CF) 0.43M0.45M0.41M0.49M0.43M0.43M0.42M
Change in Working Capital
Change in Account Payables 0.63M1.08M-0.21M1.81M-1.91M-0.85M-2.43M
Change in Accured Expenses -5.69M1.23M2.09M1.57M-3.97M1.87M-0.37M
Other Working Capital Changes 0.79M2.21M-3.92M-0.14M1.05M0.33M-0.29M
Investing Activities
Capital Expenditures 0.29M0.36M0.06M0.05M0.05M0.02M
Change in Acquisitions & Divestments 37.00M34.36M42.79M29.50M71.70M36.20M40.09M
Cash from Investing Activities 31.22M26.12M10.73M22.12M62.19M11.52M40.09M
Financing Activities
Other financing activities 5.55M6.10M5.93M21.23M3.83M3.81M2.42M
Cash from Financing Activities -0.01M0.06M-0.13M-0.03M-0.16M0.04M-0.01M
Additional items
Change in Cash -0.58M3.12M-16.69M1.34M27.80M-14.52M20.97M
Beginning Cash Balance 29.34M28.75M31.87M15.18M75.31M91.82M37.23M
Free Cash Flow -32.08M-23.42M-27.36M-20.80M-34.28M-26.09M-19.11M
Net Cash Flow -0.58M3.12M-16.69M1.34M27.80M-14.52M20.97M